

AMENDMENTS TO THE CLAIMS

In the claims, please cancel claims and 19 and amend claims as follows:

1. (currently amended) A composition comprising: a T7 ligand covalently attached to a compound, said compound selected from the list consisting of: drug, complex and polynucleotide.
2. (canceled)
3. (currently amended) The composition of claim [[2]] 1 wherein the drug comprises interferon.
4. (canceled)
5. (currently amended) The composition of claim [[4]] 1 wherein the complex consists of a liposome.
6. (currently amended) The composition of claim [[4]] 1 wherein the complex consists of a polyplex.
7. (currently amended) The composition of claim [[4]] 1 wherein the complex consists of a lipopolyplex.
8. (currently amended) The composition of claim [[4]] 1 wherein the complex comprises a polynucleotide.
9. (original) The composition of claim 8 wherein the polynucleotide consists of an expression cassette.
10. (original) The composition of claim 8 wherein the polynucleotide consists of an RNA.
11. (currently amended) The composition of claim 1 wherein the compound polynucleotide consists of an RNA function inhibitor.
12. (original) The composition of claim 1 wherein the T7 ligand comprises SEQ ID 1.
13. (original) The composition of claim 1 wherein the T7 ligand contains a functional group.
14. (original) The composition of claim 13 wherein the functional group consists of a thiol.
15. (original) The composition of claim 14 wherein the thiol consists of a cysteine.
16. (original) The composition of claim 13 wherein the functional group consists of biotin.
17. (original) The composition of claim 13 wherein the functional group consists of streptavidin.
18. (canceled)
19. (canceled)

20. (original) The composition of claim 1 wherein the T7 ligand is attached to the compound via a linker.
21. (currently amended) The composition of claim 20 wherein the linker consists of a [[PEG]] polyethylene glycol.
22. (original) The composition of claim 1 wherein the T7 ligand consists of a T7 phage.
23. (original) The composition of claim 1 wherein the T7 ligand consists of a T7 p17 protein.
24. (original) The composition of claim 1 wherein the T7 ligand consists of a T7 p17 derived peptide.
25. (original) The composition of claim 24 wherein the T7 p17 peptide consists of the T7 p17 rod domain.
26. (canceled)
27. (original) The composition of claim 1 wherein the T7 ligand consists of: T7 ligand-cysteine-PDP-streptavidin.
28. (original) The composition of claim 1 wherein the T7 ligand consists of T7 ligand-PEG-biotin.
29. (currently amended) A pharmaceutical preparation comprising: a compound selected from the list consisting of: drug, complex and polynucleotide associated with covalently attached to a T7 ligand.
30. (currently amended) A composition for targeting hepatocytes *in vivo* comprising: a T7 ligand associated with covalently attached to a compound, said compound selected from the list consisting of: drug, complex and polynucleotide.